目的　制备人肝癌特异性单克隆抗体 HAb18的 F(ab′) 2 片段导向抗肝癌阿霉素 (ADR)白蛋白(HSA)免疫毫微球 (HAb18F(ab′) 2 - ADR- HSA- NP) ,并研究其体外靶向肝癌细胞和杀伤肝癌细胞的作用。方法　采用乳化高温固化法制备阿霉素白蛋白毫微球 (ADR- HSA- NP)后 ,应用改进的 N-琥珀酰亚胺基 - 3- (2 -吡啶二硫 )丙酸酯 (SPDP)法制备 HAb18F(ab′) 2 - ADR- HSA- NP。在光镜和电镜下观察体外 HAb18F(ab′) 2 - ADR- HSA- NP和 ADR- HSA- NP与肝癌细胞株 SMMC- 772 1的结合特性 ,并用 3H- Td R法测定两种微球体外杀伤肝癌细胞株SMMC- 772 1的作用。结果　在荧光染色后 ,HAb18F(ab′) 2 - ADR- HSA - NP表面发出明亮黄绿色荧光 ,而 ADR-HSA- NP未见荧光。 HAb18F(ab′) 2 - ADR- HSA- NP能结合肝癌细胞株 SMMC- 772 1,且能呈剂量依赖地有效杀伤肝癌细胞株 SMMC- 772 1,而 ADR- HSA- NP不能结合和明显杀伤肝癌细胞株 SMMC- 772 1。两种微球均不能结合和杀伤人大肠癌细胞株 SW1116。结论　 HAb18F(ab′) 2 - ADR- HSA - NP具良好的体外特异性结合并杀伤人肝癌细胞 OBJECTIVE To prepare F (ab ’) 2 fragments of human hepatoma-specific monoclonal antibody HAb18 for anti-hepatoma adriamycin (HSA) immunosuppression (HAb18F (ab’) 2 - ADR- HSA- NP) , And to study its role in targeting hepatoma cells and killing hepatoma cells in vitro. Methods After the adriamycin albumin nanospheres (ADR-HSA-NP) were prepared by emulsification and high temperature curing, the modified N-succinimidyl 3- (2-pyridyldithio) propionate (SPDP) Preparation of HAb18F (ab ’) 2 - ADR - HSA - NP. The binding characteristics of HAb18F (ab ’) 2 - ADR - HSA - NP and ADR - HSA - NP in vitro to SMMC - 772 1 cells were observed under light microscope and electron microscope. The 3H - Td R To kill the hepatoma cell line SMMC-772 1. Results After the fluorescent staining, the surface of HAb18F (ab ’) 2 - ADR - HSA - NP emitted bright yellow - green fluorescence, while the fluorescence of ADR - HSA - NP was not observed. HAb18F (ab ’) 2 - ADR - HSA - NP can bind to hepatocellular carcinoma cell line SMMC - 772 1 and effectively kill hepatocellular carcinoma cell line SMMC - 772 1 in a dose - dependent manner, while ADR - HSA - NP can not bind to and significantly kill liver cancer Cell line SMMC-772 1. Both microspheres can not bind to and kill human colorectal cancer cell line SW1116. Conclusion HAb18F (ab ’) 2 - ADR - HSA - NP has good in vitro specific binding and killing human liver cancer cells